US 12,215,146 B2
Antibody variants
Esther Maria Furrer, Rheinfelden (CH)
Assigned to Tillotts Pharma AG, Rheinfelden (CH)
Appl. No. 16/648,185
Filed by Tillotts Pharma AG, Rheinfelden (CH)
PCT Filed Sep. 11, 2018, PCT No. PCT/EP2018/074523
§ 371(c)(1), (2) Date Mar. 17, 2020,
PCT Pub. No. WO2019/057565, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 17191988 (EP), filed on Sep. 19, 2017.
Prior Publication US 2020/0255511 A1, Aug. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/241 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 5 Claims
 
1. An antibody comprising a TNFα-binding domain and an FcRn-binding site, wherein said antibody has a high affinity to human FcRn at pH 6, said high affinity being characterized by a dissociation equilibrium constant (KD) of less than 500 nM, further wherein said antibody has no affinity or a low affinity to human FcRn at pH 7.4, said low affinity being characterized by a KD of greater than 10 μM, further wherein the amino acid sequence of the antibody comprises the amino acids 380A and 434A, wherein the numbering of amino acid residues is according to the EU index, further wherein the antibody comprises (i) a VL domain comprising a CDR1 region having the amino acid sequence as shown in SEQ ID NO:3, a CDR2 region having the amino acid sequence as shown in SEQ ID NO:4, and a CDR3 region having the amino acid sequence as shown in SEQ ID NO:5, and (ii) a VH domain comprising a CDR1 region having the amino acid sequence as shown in SEQ ID NO:6, a CDR2 region having the amino acid sequence as shown in SEQ ID NO:7, and a CDR3 region having the amino acid sequence as shown in SEQ ID NO:8.